Filing Details
- Accession Number:
- 0001209191-18-058384
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-11-13 18:29:40
- Reporting Period:
- 2018-11-08
- Accepted Time:
- 2018-11-13 18:29:40
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1131324 | Genomic Health Inc | GHDX | Services-Medical Laboratories (8071) | 770552594 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1649689 | J James Vaughn | 301 Penobscot Drive Redwood City CA 94063 | Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-11-08 | 3,000 | $31.12 | 20,542 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-11-08 | 1,100 | $83.94 | 19,442 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-11-08 | 1,300 | $85.18 | 18,142 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-11-08 | 300 | $85.84 | 17,842 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-11-08 | 300 | $89.07 | 17,542 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (right to buy) Holding | Disposition | 2018-11-08 | 3,000 | $0.00 | 3,000 | $31.12 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
36,772 | 2025-02-13 | No | 4 | M | Direct |
Footnotes
- Includes an aggregate of 15,534 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 6, 2018.
- Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- Represents weighted average sale price. Actual sale prices ranged from $83.66 to $84.20.
- Represents weighted average sale price. Actual sale prices ranged from $84.66 to $85.64.
- Represents weighted average sale price. Actual sale prices ranged from $85.77 to $85.90.
- Represents weighted average sale price. Actual sale prices ranged from $88.88 to $89.42.
- The option became exercisable as to 25% of the shares on February 13, 2016, and becomes exercisable as to 1/48th of the shares each full month thereafter.